VNN2

Across TCGA pan-cancer cohorts, VNN2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated VNN2 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher VNN2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated VNN2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, GBM, and LSCC are the cancer types where VNN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	III,IV	0.218	0.743	.002	10	view →
GBM	DFS	Quartile	All	0.250	0.502	.040	3	view →
LSCC	DFS	Median	III,IV	1.000	0.867	.045	1	view →
PDAC	DFS	Quartile	All	0.713	0.872	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

VNN2–LUAD (OS)

Open the LUAD breakdown →